TL;DR

  • The Trial: EVOKE and EVOKE+ — the largest GLP-1 Alzheimer’s RCT ever conducted (n=3,808, Phase 3, The Lancet, November 2025). Oral semaglutide 14mg vs placebo, 2 years.
  • The Result: Primary endpoint missed in both trials. No meaningful difference in cognitive decline on CDR-SB or any secondary measure.
  • The Nuance: Inflammatory biomarkers improved ~10% — but that didn’t translate to clinical benefit. Meanwhile, the older drug liraglutide showed promising secondary signals in a Phase 2b trial.

EVOKE Trial Key Numbers

Why Scientists Bet on Ozempic for Alzheimer’s

The GLP-1 receptor agonist class — which includes semaglutide (Ozempic, Wegovy) and liraglutide (Victoza) — has steadily expanded its therapeutic footprint beyond diabetes and obesity. Cardiovascular protection, kidney disease, heart failure: over recent years, the drug class has demonstrated meaningful benefits across multiple organ systems.

The brain was a natural next frontier. GLP-1 receptors are present in neurons throughout the central nervous system. In animal models, GLP-1 receptor agonists reduce neuroinflammation, promote cellular autophagy, enhance mitochondrial function, and modulate neurotransmitter release. Real-world data added fuel: propensity-matched cohort analyses found that GLP-1 drug users had up to 70% lower observed rates of dementia compared to matched controls.

Against this backdrop, Novo Nordisk enrolled 3,808 people with early Alzheimer’s disease in what became the largest clinical trial of any GLP-1 drug in neurodegeneration. The scientific community watched closely.

What EVOKE Actually Found

Published on November 24, 2025 in The Lancet, the EVOKE and EVOKE+ trials were parallel Phase 3 randomized, double-blind, placebo-controlled studies.

Participants were aged 55 to 85, amyloid-positive (confirmed by biomarker testing), with mild cognitive impairment or mild Alzheimer’s dementia. EVOKE+ extended enrollment to include participants with extensive cerebral small vessel disease. Both groups received oral semaglutide 14mg or placebo daily for 104 weeks.

The primary endpoint was change from baseline in CDR-SB (Clinical Dementia Rating–Sum of Boxes), a well-validated measure of cognitive and functional decline.

The results, in the study’s own terms: EVOKE reported a difference of –0.06 between semaglutide and placebo — not statistically significant. EVOKE+ reported +0.15 — also not significant. The MMSE, MoCA, ADAS-Cog-13, and ADCOMS scales all told the same story. No difference. The trial extension period was cancelled.

Semaglutide vs Liraglutide in Alzheimer's: Different Results

The Biomarker Paradox

Here is where the data gets genuinely interesting — and instructive.

Semaglutide was not without effect. Plasma biomarkers including hs-CRP (a marker of systemic inflammation) improved by approximately 10% in the treatment arm. This is consistent with GLP-1’s known anti-inflammatory mechanisms. The drug was doing something in the body.

But that something did not reach the brain in a clinically meaningful way. Cognitive function did not improve. Daily functional capacity did not improve.

This is a pattern that has haunted Alzheimer’s research for two decades. In trial after trial, drugs that successfully clear amyloid plaques, reduce tau protein accumulation, or improve selected biomarkers fail to translate those lab improvements into what actually matters: whether patients remember their families, manage their medications, or navigate their homes. The EVOKE results add semaglutide to a long list of drugs that moved the markers without moving the needle on disease.

Why? Researchers have offered several hypotheses: limited blood-brain barrier penetration by semaglutide at clinical doses, insufficient GLP-1 receptor density in the specific brain regions affected by Alzheimer’s pathology, or the possibility that the intervention came too late in the disease process — after neurodegeneration had already become too extensive for metabolic intervention to reverse.

The Liraglutide Counterpoint

Published concurrently in Nature Medicine, the ELAD Phase 2b trial of liraglutide (n=204, 12 months) produced a more complicated picture.

Like EVOKE, it missed its primary endpoint — change in cerebral glucose metabolic rate showed no statistically significant difference. But secondary analyses told a different story. The liraglutide group showed approximately 18% less cognitive decline on an executive function subscale (ADAS-Exec, p=0.01 unadjusted). Perhaps more striking: brain atrophy in the temporal lobe — the region that controls memory, language, and learning — was reduced by nearly 50% compared to placebo.

These are secondary outcomes from a 204-person Phase 2b trial. They cannot be interpreted as proof of efficacy. Pre-specified secondary analyses in small trials carry substantial risk of false positives. But they do raise a question that the field is now actively debating: why might an older, structurally different GLP-1 agonist show cognitive signals that a newer, more potent one does not?

Proposed explanations include differences in blood-brain barrier penetration, distinct receptor binding profiles, or potentially that liraglutide’s shorter half-life results in different CNS receptor engagement patterns. No consensus has emerged.

GLP-1 to Brain: Where the Pathway Breaks Down

What This Means For You

Three practical takeaways from these results, calibrated to what the evidence actually supports.

1. GLP-1 drugs remain valuable metabolic tools — but Alzheimer’s prevention is not yet one of their validated uses. If you are taking semaglutide or liraglutide for diabetes, obesity, or cardiovascular risk, EVOKE does not change the risk-benefit calculus for those indications. What it does is remove Alzheimer’s prevention from the list of confirmed benefits. The real-world observational data showing lower dementia risk in GLP-1 users is likely explained by the drugs’ metabolic and cardiovascular effects — not a direct neuroprotective mechanism.

2. The interventions with the strongest current evidence for dementia prevention remain lifestyle-based. A 2024 Lancet Commission report identified 14 modifiable risk factors that together account for roughly 45% of dementia cases worldwide — including physical inactivity, hypertension, diabetes, obesity, hearing loss, depression, smoking, and low social engagement. Regular aerobic exercise consistently ranks as the single strongest behaviorally modifiable protective factor, associated with 20–30% lower dementia risk in meta-analyses. Managing cardiovascular risk factors (blood pressure, blood glucose, cholesterol) has particularly strong evidence for vascular-component dementias.

3. The earlier an intervention occurs, the more likely it is to matter. One of the key design questions the EVOKE failure raises is timing. Participants already had confirmed amyloid pathology and symptomatic cognitive impairment. By that stage, the neurological damage may already be too extensive for a single metabolic agent to reverse. Future trials targeting presymptomatic individuals — those with amyloid positivity but not yet symptomatic — may tell a different story.

The Caveats

These are Phase 3 trials — the gold standard of evidence. Unlike observational studies or animal model data, the EVOKE results represent the most rigorous test available. When a drug fails Phase 3 in 3,808 patients over two years, that is a meaningful negative result.

The liraglutide secondary findings are Phase 2b, small, and not primary. Interpreting them as proof of efficacy would be premature. They are hypothesis-generating.

Alzheimer’s disease is heterogeneous. EVOKE enrolled amyloid-positive patients, but Alzheimer’s pathology involves multiple interacting processes — tau accumulation, synaptic dysfunction, vascular damage, neuroinflammation. A drug that targets one pathway is unlikely to arrest all of them simultaneously. Combination approaches (GLP-1 plus anti-amyloid antibodies, for instance) remain scientifically plausible.

The Bottom Line

EVOKE is a significant negative trial — significant because of its scale (3,808 patients), its rigor (Phase 3 double-blind RCT), its prominence (The Lancet), and the enormous scientific and popular hope that surrounded it.

The result does not close the book on GLP-1 drugs and the brain. It does close the chapter on oral semaglutide as a treatment for existing mild Alzheimer’s disease. Future research will likely shift toward earlier intervention, higher CNS-penetrant formulations, or combination strategies that attack Alzheimer’s from multiple angles simultaneously.

For now, the most evidence-supported protection against cognitive decline remains what it has been for years: stay physically active, manage your cardiovascular risk factors, stay socially and cognitively engaged, and sleep adequately. Not a single molecule. A way of living.

This content is for informational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition.

Sources

  • The Lancet (November 24, 2025): EVOKE and EVOKE+ Phase 3 RCTs — oral semaglutide 14mg in Alzheimer’s disease (n=3,808, Novo Nordisk)
  • Nature Medicine (2025): “Liraglutide in mild to moderate Alzheimer’s disease: a phase 2b clinical trial” (ELAD, n=204)
  • Alzheimer’s Association (2025): Statement on oral semaglutide Phase 3 topline data
  • Alzheimer’s & Dementia (2024): “Dementia care in a rapidly aging society” — Korea epidemiology
  • Lancet Commission on Dementia Prevention, Intervention, and Care (2024 update)